Bayer Sees Room For Third-To-Market Darolutamide In Prostate Cancer
Executive Summary
ASCO GU: Darolutamide is important for the company's oncology portfolio, but does it have enough to compete against J&J's Erleada and Pfizer/Astellas' Xtandi?
You may also be interested in...
ASCO 2020: Can Xtandi PROSPER In Prostate OS Data Battle?
While Xtandi has positive new survival data in prostate cancer, other rivals in the competitive market are reporting the same at ASCO.
Can Zydus Cadila's Cut-Price Enzalutamide Shake Up Indian Market?
Cadila Healthcare has launched a generic version of Astellas/Pfizer’s prostate cancer therapy Xtandi in India at a sharp discount of 70-90% to existing brands and hopes the lower financial burden on patients will aid adherence.
Xarelto And Eylea Keep Bayer Buoyant
The German major's two leading products continue to perform well but there are not many potential blockbusters in the pipeline.